文献速递泌尿生殖与妇科肿瘤放疗

ADT对接受近距离放疗推量联合外照射的不利中危前列腺癌患者是否有益?倾向评分匹配分析

Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis.
PubMed 文献 · Radiother Oncol · 2020-06-30

该回顾性研究纳入326例NCCN不利中危前列腺癌患者,均接受15 Gy HDR近距离放疗推量联合37.5 Gy/15次外照射。经倾向评分1:2匹配后比较52例接受ADT与104例未接受ADT患者,中位随访分别为3.4年和5.5年。ADT组生化失败无生存(BFFS)显著改善(分层log-rank p=0.043),3年和6年BFFS分别为98%和90% vs 92%和82%,去势抵抗无生存和转移无生存无显著差异。

要点

  • 短程ADT(中位6个月)显著改善不利中危前列腺癌患者HDR近距离放疗推量后的BFFS。
  • ADT组3年和6年BFFS分别为98%和90%,非ADT组为92%和82%(p=0.043)。
  • 去势抵抗无生存和转移无生存两组间无显著差异。

核心结论

  • 短程ADT可提高接受HDR近距离放疗推量联合外照射的不利中危前列腺癌患者的生化失败无生存。

研究设计与样本

  • 单中心回顾性收集2009至2016年326例连续NCCN不利中危前列腺癌患者,均接受15 Gy HDR近距离放疗推量联合37.5 Gy/15次外照射至前列腺及近端精囊。
  • 采用倾向评分模型按1:2匹配,52例接受ADT患者与104例未接受ADT患者进行比较。
  • 主要终点为生化失败无生存(BFFS),采用Kaplan-Meier估计和分层log-rank检验(校正匹配设计)比较BFFS、去势抵抗无生存(CRFS)和转移无生存(MFS)。

主要发现

  • ADT组中位随访3.4年,非ADT组中位随访5.5年,两组基线无显著差异。
  • ADT中位总疗程6个月(IQR 4-6),HDR近距离放疗前中位给药时间2.7个月(IQR 1.7-4.3)。
  • ADT组BFFS显著改善(分层log-rank p=0.043),3年和6年BFFS分别为98%和90%,非ADT组分别为92%和82%。
  • CRFS和MFS两组间均未检测到显著差异。

关键数值与推荐

  • ADT组3年BFFS为98%,6年BFFS为90%;非ADT组3年BFFS为92%,6年BFFS为82%(p=0.043)。
  • ADT中位总疗程6个月(IQR 4-6),HDR近距离放疗前中位给药时间2.7个月(IQR 1.7-4.3)。

临床怎么用

  • 对于接受HDR近距离放疗推量联合外照射的不利中危前列腺癌患者,可考虑联合短程ADT以改善生化控制。
  • ADT疗程和时机可参考本研究的中位6个月总疗程及HDR近距离放疗前中位2.7个月开始给药。

局限性

  • 本研究为单中心回顾性分析,样本量有限(匹配后52例ADT vs 104例非ADT)。
  • 两组中位随访时间不一致(ADT组3.4年 vs 非ADT组5.5年)。
  • 原文未报告CRFS和MFS的具体数值及P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the role of androgen deprivation therapy (ADT) in unfavorable intermediate risk (UIR) prostate cancer patients treated with high-dose rate (HDR) brachytherapy (BT) boost. MATERIAL AND METHODS: Data from 326 consecutive NCCN UIR prostate cancer patients treated in a single institution from 2009 to 2016 with 15 Gy HDR-BT boost plus 37.5 Gy external beam radiotherapy (EBRT) in 15 fractions to prostate and proximal seminal vesicles were retrospectively collected. Baseline information was collected and patients receiving vs. not receiving ADT were matched using a propensity-score model. Primary endpoint was biochemical-failure-free survival (BFFS). Kaplan-Meier estimates and stratified log-rank tests (adjusting for matched design) were used to compare BFFS, castration-resistance (CRFS) and metastasis free survival (MFS) outcomes between both groups. RESULTS: A total of 326 patients were included in the analysis of which 52 ADT patients were matched to 104 non-ADT patients in a 1:2 ratio. Median follow-up was 3.4 years and 5.5 years for ADT and non-ADT respectively. No significant baseline differences were observed. ADT was used for a median total time of 6 months (interquartile range [IQR]: 4-6) and delivered a median time of 2.7 months (IQR: 1.7-4.3) prior to HDR-BT. BFFS was significantly improved in the ADT group (stratified log-rank: p = 0.043) with 3-year and 6-year BFFS of 98% and 90% for the ADT group and 92% and 82% for the non-ADT group, respectively. No significant differences were detected for CRFS or MFS. CONCLUSION: Short-term ADT increased BFFS in UIR prostate cancer patients treated with HDR-BT boost plus EBRT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Mendez LC, Martell K, Warner A, et al. Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis. Radiother Oncol. 2020. PMID: 32619455. doi:10.1016/j.radonc.2020.06.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。